Puma Biotechnology, Inc. (PBYI) Income Statement
PBYI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPBYI revenue and net income
Where PBYI's revenue goes
2025Each bar shows an amount and its share of revenue. PBYI kept 13.6% of revenue as net income.
PBYI profit margins
PBYI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −0.9% | +0.0% | +0.3% | — |
| Gross profit | +2.5% | −0.5% | −1.7% | — |
| Operating income | +20.5% | +16.3% | — | — |
| Net income | +2.8% | +2,396.3% | — | — |
| EPS (diluted) | −16.7% | +48.1% | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PBYI quarterly EPS vs estimates
Puma Biotechnology beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 5, 2026 (estimate $0.06).
PBYI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M | $225.1M | $272.3M | $251.0M | $27.7M | $0 |
| Cost of revenue | $58.2M | $64.4M | $62.7M | $55.1M | $63.7M | $39.4M | $36.8M | $34.6M | $5.6M | $1.1M |
| Gross profit | $170.2M | $166.1M | $173.0M | $172.9M | $189.5M | $185.7M | $235.4M | $216.4M | $22.1M | −$1.1M |
| Research & development | $62.1M | $54.9M | $50.4M | $52.2M | $71.9M | $97.7M | $132.9M | $164.9M | $207.8M | $222.8M |
| Sales, general & admin | $71.2M | $81.2M | $89.3M | $90.0M | $116.3M | $118.6M | $141.6M | $146.2M | $106.7M | $53.8M |
| Total operating expenses | $132.9M | $135.1M | $140.3M | $149.2M | $188.2M | $216.1M | $311.0M | $311.1M | $314.5M | $276.6M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M | −$30.4M | −$75.6M | −$94.7M | −$292.4M | −$276.6M |
| Interest income | $4.1M | $4.7M | $2.4M | $813,000 | $160,000 | $500,000 | $2.8M | $1.8M | $1.3M | $958,000 |
| Interest expense | $6.6M | $12.5M | $13.3M | $11.6M | $12.8M | $14.0M | $15.0M | $11.0M | $720,000 | $958,000 |
| Income before taxes | $35.8M | $24.1M | $22.7M | $457,000 | −$28.8M | −$59.8M | −$75.5M | −$113.6M | −$292.0M | −$276.0M |
| Income taxes | $4.7M | −$6.2M | $1.1M | $455,000 | $324,000 | $207,000 | $53,000 | −$7.9M | −$2.2M | −$2.1M |
| Net income | $31.1M | $30.3M | $21.6M | $2,000 | −$29.1M | −$60.0M | −$75.6M | −$113.6M | −$292.0M | −$276.0M |
| EBITDA | $53.3M | $48.1M | $47.5M | $21.9M | −$4.7M | −$35.7M | −$52.4M | −$95.2M | −$288.4M | −$275.5M |
| EPS (diluted) | $0.65 | $0.78 | $0.62 | $0.20 | −$0.02 | −$0.83 | −$0.48 | −$1.21 | −$5.61 | −$5.60 |
| Gross margin | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% | 79.8% | — |
| Operating margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% | −13.5% | −27.8% | −37.7% | −1,055.6% | — |
| Net margin | 13.6% | 13.1% | 9.2% | 0.0% | −11.5% | −26.7% | −27.8% | −45.3% | −1,054.2% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.5M | $44.8M | $75.5M | $54.5M | $52.4M | $46.0M | $59.1M | $80.5M | $47.1M | $43.8M | $72.2M | $56.1M |
| Cost of revenue | $12.5M | $10.4M | $23.1M | $12.2M | $12.3M | $10.6M | $13.9M | $29.1M | $10.7M | $10.7M | $24.3M | $13.3M |
| Gross profit | $44.0M | $34.4M | $52.3M | $42.3M | $40.1M | $35.5M | $45.2M | $51.4M | $36.4M | $33.0M | $47.9M | $42.8M |
| Research & development | $18.9M | $19.8M | $16.8M | $15.9M | $15.5M | $13.9M | $15.2M | $12.5M | $13.6M | $13.6M | $12.9M | $11.4M |
| Sales, general & admin | $17.5M | $18.4M | $18.4M | $17.0M | $18.4M | $17.4M | $17.0M | $16.9M | $25.3M | $21.8M | $20.2M | $22.2M |
| Total operating expenses | $36.4M | $38.2M | $35.2M | $32.7M | $33.5M | $31.5M | $31.8M | $29.4M | $38.6M | $35.3M | $33.1M | $34.2M |
| Operating income | $7.6M | −$3.8M | $17.1M | $9.6M | $6.6M | $4.0M | $13.4M | $22.1M | −$2.2M | −$2.3M | $14.8M | $8.6M |
| Interest income | $831,000 | $1.0M | $977,000 | $1.0M | $956,000 | $1.1M | $1.2M | $1.3M | $1.2M | $972,000 | $719,000 | $689,000 |
| Interest expense | $180,000 | $731,000 | $1.1M | $1.5M | $1.8M | $2.2M | $2.6M | $3.1M | $3.4M | $3.4M | $3.4M | $3.3M |
| Income before taxes | $8.2M | −$3.4M | $17.1M | $9.2M | $6.2M | $3.3M | $12.2M | $20.6M | −$4.2M | −$4.6M | $12.8M | $6.0M |
| Income taxes | $56,000 | $326,000 | $3.7M | $399,000 | $310,000 | $293,000 | −$7.1M | $291,000 | $378,000 | $220,000 | $536,000 | $213,000 |
| Net income | $8.2M | −$3.8M | $13.4M | $8.8M | $5.9M | $3.0M | $19.3M | $20.3M | −$4.5M | −$4.8M | $12.3M | $5.8M |
| EBITDA | $10.9M | −$112,000 | $20.9M | $13.5M | $10.8M | $8.2M | $17.7M | $26.6M | $2.1M | $1.7M | $18.3M | $12.2M |
| EPS (diluted) | $0.16 | −$0.04 | $0.26 | $0.21 | $0.12 | $0.06 | $0.43 | $0.45 | −$0.05 | −$0.05 | $0.26 | $0.17 |
| Gross margin | 77.9% | 76.7% | 69.3% | 77.7% | 76.5% | 77.1% | 76.4% | 63.9% | 77.4% | 75.5% | 66.3% | 76.3% |
| Operating margin | 13.4% | −8.5% | 22.7% | 17.6% | 12.7% | 8.7% | 22.6% | 27.4% | −4.6% | −5.3% | 20.5% | 15.3% |
| Net margin | 14.5% | −8.4% | 17.8% | 16.2% | 11.2% | 6.5% | 32.7% | 25.2% | −9.6% | −11.0% | 17.0% | 10.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PBYI's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PBYI financial results
In fiscal year 2025 (ended December 31, 2025), Puma Biotechnology reported revenue of $228.4 million, down 0.9% from the year before. It had net income of $31.1 million (up 2.8%), a net profit margin of 13.6%. Diluted earnings per share came to $0.65. Over five years revenue grew at an average rate of 0.3% a year.
See the PBYI stock overview for the latest quote and news, or the PBYI chart for price history and technical indicators.
PBYI income statement FAQ
What is Puma Biotechnology's annual revenue?
Puma Biotechnology reported total revenue of $228.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 0.9% from $230.5 million the previous year.
Is Puma Biotechnology profitable?
Yes. Puma Biotechnology reported net income of $31.1 million in fiscal 2025, a net profit margin of 13.6%; its operating margin was 16.3%.
What is Puma Biotechnology's gross margin?
Puma Biotechnology's gross margin was 74.5% in fiscal 2025: for every $100 of revenue, Puma Biotechnology kept $75 after the direct cost of its products and services.
How much does Puma Biotechnology spend on research and development?
Puma Biotechnology spent $62.1 million on research and development in fiscal 2025, 27.2% of revenue.
How fast is Puma Biotechnology growing?
Revenue grew 0.3% a year on average over the last five fiscal years, from $225.1 million to $228.4 million.
What are Puma Biotechnology's earnings per share?
Puma Biotechnology earned $0.65 per diluted share in fiscal 2025, compared with $0.78 a year earlier.
When will Puma Biotechnology report its next earnings?
Puma Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Puma Biotechnology's fiscal year end?
Puma Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.